Benzinga's Top Pre-Market Gainers
Eli Lilly & Co (NYSE: LLY) soared 4.95% to $44.50 in the pre-market trading. Eli Lilly reported that primary endpoints were not met in two Phase 3 trials of solanezumab.
ReneSola Ltd (NYSE: SOL) added 3.35% to $1.85 in the pre-market session. ReneSola reported a loss in the second quarter.
Amarin Corporation plc (NASDAQ: AMRN) moved up 3.19% to $12.61 in the pre-market session. Amarin had $250.26 million in total cash for the latest quarter.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.